title: The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems.
abstract: We evaluated the effect of a β-propiolactone (BPL)-inactivated coxsackievirus A16 (CA16) vaccine, using three immunogenicity evaluation and two animal challenge systems. A CA16 virus strain, named 419, was used as the production strain. Another CA16 strain, named 1131, was isolated and used as the challenge strain in intracerebral inoculation of neonatal mice for the calculation of median lethal dose (LD 50). In the passive and maternal antibody-protection challenge systems, all results indicated that the vaccine could protect mouse pups from lethal challenge with the CA16 virus. In the immunogenicity systems, three types of animal (mouse, rat, and cynomolgus monkey), were immunized with the 419/CA16 vaccine. The dose-effect relationship and the antibody-generation routine were described. The CA16 vaccine induced a more potent serum antibody effect in rat than in mouse. The serum antibody titer was detectable more than 63 days after the initial vaccination. We also identified tools to evaluate the effect of the BPL-inactivated CA16 vaccine.
authors.affiliation: Hualan Biological Engineering Inc.; Xinxiang, PR China; National Key laboratory of Biochemical Engineering; Institute of Process Engineering; Chinese Academy of Sciences; Beijing, PR China.
authors.forename: Wen
authors.initials: W
authors.lastname: Qi An
authors.affiliation: National Key laboratory of Biochemical Engineering; Institute of Process Engineering; Chinese Academy of Sciences; Beijing, PR China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Guo Su
authors.affiliation: Hualan Biological Engineering Inc.; Xinxiang, PR China.
authors.forename: Ruo
authors.initials: R
authors.lastname: Wen Pan
authors.affiliation: Hualan Biological Engineering Inc.; Xinxiang, PR China.
authors.forename: Bao
authors.initials: B
authors.lastname: Ping Yang
authors.affiliation: Hualan Biological Engineering Inc.; Xinxiang, PR China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Chao Zhang
authors.affiliation: Hualan Biological Engineering Inc.; Xinxiang, PR China.
authors.forename: Liang
authors.initials: L
authors.lastname: Shi
authors.affiliation: Hualan Biological Engineering Inc.; Xinxiang, PR China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D003384:Coxsackievirus Infections / Q000517:prevention & control*; D004202:Disinfectants / Q000378:metabolism*; D004306:Dose-Response Relationship, Immunologic; D004770:Enterovirus / Q000187:drug effects / Q000276:immunology*; D005260:Female; D007112:Immunity, Maternally-Acquired; D007116:Immunization, Passive; D007928:Lethal Dose 50; D008252:Macaca fascicularis; D008807:Mice, Inbred BALB C; D011420:Propiolactone / Q000378:metabolism*; D017207:Rats, Sprague-Dawley; D016019:Survival Analysis; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D038301:Virus Inactivation
chemical_list: D000914:Antibodies, Viral; D004202:Disinfectants; D015164:Vaccines, Inactivated; D014765:Viral Vaccines; D011420:Propiolactone
keywords: challenge systems; coxsackievirus A16; enterovirus; immunogenicity; vaccine